Anhui Huaheng Biotechnology Co., Ltd.

Equities

688639

CNE1000052M6

Food Processing

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
107.5 CNY +0.49% Intraday chart for Anhui Huaheng Biotechnology Co., Ltd. -1.19% -14.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Anhui Huaheng Biotechnology's Q1 Profit Jumps 7% MT
Anhui Huaheng Biotechnology's 2023 Profit Jumps 40% MT
Certain A Shares of Anhui Huaheng Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI
Anhui Huaheng Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Rate Cut Plans Boost China Stocks; Huaheng Biotechnology Jumps 9% MT
Huaheng Biotechnology to Set Up Subsidiary, Production Plant for 700 Million Yuan MT
Huaheng Biotechnology Gets Rights to Ouhe Biotechnology's Biological Arginine Production Technology MT
Anhui Huaheng Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Anhui Huaheng Biotechnology Co., Ltd.'s Equity Buyback Plan announced on August 11, 2023. CI
Anhui Huaheng Biotechnology Co., Ltd.'s Equity Buyback announced on August 11, 2023, has closed with 496,600 shares, representing 0.32% for CNY 49.98 million. CI
Anhui Huaheng Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Anhui Huaheng Biotechnology Co., Ltd.'s Equity Buyback Plan announced on August 11, 2023. CI
Anhui Huaheng Biotechnology Co., Ltd.(XSSC:688639) added to S&P Global BMI Index CI
Anhui Huaheng Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wuhan Ruijiakang Biotechnology Co., Ltd. announced that it has received CNY 20 million in funding from Anhui Huaheng Biotechnology Co., Ltd., Suzhou Kaifeng Zhengde Investment Management Co., Ltd. CI
Anhui Huaheng Biotechnology Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Anhui Huaheng Biotechnology Co., Ltd. authorizes a Buyback Plan. CI
Anhui Huaheng Biotechnology Acquires Marketing Rights to Ouhe Biotechnology's Phytic Acid Technology MT
Anhui Huaheng Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Anhui Huaheng Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Huaheng Biotechnology Unit Earmarks 400 Million Yuan for Mongolia Plant MT
Anhui Huaheng Biotechnology Co., Ltd. announces decision of Shareholder/Board on the transaction CI
Anhui Huaheng Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Anhui Huaheng Biotechnology Co., Ltd. announced that it expects to receive CNY 1.7270709 billion in funding CI
Tianjin Zhihe Biotechnology Co., Ltd. announced that it expects to receive CNY 10 million in funding from Anhui Huaheng Biotechnology Co., Ltd. CI
Chart Anhui Huaheng Biotechnology Co., Ltd.
More charts
Anhui Huaheng Biotechnology Co Ltd is a China-based company specializing in the research and development, production and sales of amino acids and other bio-based products based on alanine series products. The Company is a high-tech enterprise focusing on synthetic biotechnology and mainly engaged in the research and development, production and sales of amino acid and its derivative products. The Company's main products include alanine series products (L-alanine, DL-alanine, β-alanine), calcium D-pantothenate and α-arbutin. The Company's products are mainly used in the fields of medicine and health products, daily chemicals, food and food additives. The Company distributes its products and services within the domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
107.5 CNY
Average target price
135.1 CNY
Spread / Average Target
+25.61%
Consensus
  1. Stock Market
  2. Equities
  3. 688639 Stock
  4. News Anhui Huaheng Biotechnology Co., Ltd.
  5. Huaheng Biotechnology Gets Rights to Ouhe Biotechnology's Biological Arginine Production Technology